Cabaletta Bio (CABA)

• Market cap: $116M
• 1 day: 3.03%
• 5 days: -13.45%
• 1 month: 5.31%
• 3 months: -49.36%
• 6 months: -71.43%
• Year to date: -89.26%
• 1 year: -88.81%
• 5 years: -76.51%
• 10 years: -76.20%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Employees: 154

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $992K | Put options by funds: $604K

31% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 35

7.48% less ownership

Funds ownership: 105.84% [Q2] → 98.36% (-7.48%) [Q3]

15% less funds holding

Funds holding: 142 [Q2] → 120 (-22) [Q3]

41% less capital invested

Capital invested by funds: $382M [Q2] → $227M (-$155M) [Q3]

52% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 42

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 152% upside
• Avg. target: $11.75 394% upside
• High target: $25 950% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Evercore ISI Group Gavin Clark-Gartner 40% 1-year accuracy 4 / 10 met price target	152% upside $6	In-Line Downgraded	20 Dec 2024
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target	152% upside $6	Equal-Weight Downgraded	19 Dec 2024
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target	950% upside $25	Buy Reiterated	18 Nov 2024
UBS Trung Huynh 40% 1-year accuracy 2 / 5 met price target	320% upside $10	Buy Initiated	10 Oct 2024